Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
KeywordCompanyEPIC/TIDMSEDOL/ISINNews
Search
Price
Announcements
Fundamentals
News
Article
RSS
Omega Diagnostics Gp (ODX)
Add to Alerts list
Print Mail a friend
Thursday 02 July, 2020
Omega Diagnostics Gp
Approval for sale in India
RNS Number : 8295R
Omega Diagnostics Group PLC
02 July 2020
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Approval for sale in India
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that its CE-Marked Mologic ELISA1 antibody test has been approved for testing of COVID-19 in India.
Yesterday the Central Drugs Standard Control Organization, part of the Ministry of Health & Family Welfare, published a list of approved Rapid / CLIA / ELISA kits approved for testing of COVID-19, which included Omega's ELISA antibody test.
Approval for sale remains conditional on the submission of supporting technical data and the Company is confident that this submission will be successful, and that Omega will be able to sell its ELISA antibody test directly into this potentially significant target market. The laboratory-based ELISA antibody test has high quality performance data and has been independently validated by the Liverpool School of Tropical Medicine and St George's, University of London.
Whilst the quantum of future sales in unknown at this stage, India is clearly a significant addressable market for COVID-19 antibody testing and Omega will use its direct sales team in India to establish commercial roll-out in the region. The Company expects to update shareholders on first commercial orders as they are received.
Colin King, CEO of Omega commented: "I am delighted that we have received approval to sell the Mologic ELISA antibody test in India as this is a key target market. We have an established direct sales team and we believe a reliable and high-performance antibody test will be very attractive to our laboratory customers. India is one of the fastest growing economies in the world and has a population of over 1.3 billion people. Clearly this is an important market for us to target and I look forward to updating shareholders on our commercial traction."